Thrombotic microangiopathy in haematopoietic stem cell transplantation: Diagnosis and treatment

Drugs

Volumn 69, Issue 2, 2009, Pages 183-198

  Choi, Cecilia M ^a   Schmaier, Alvin H ^a   Snell, Michael R ^b   Lazarus, Hillard M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTIINFLAMMATORY AGENT; BUSULFAN; CALCINEURIN INHIBITOR; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACLIZUMAB; DEFIBROTIDE; ETANERCEPT; ETOPOSIDE; FLUDARABINE; FRESH FROZEN PLASMA; ICOSAPENTAENOIC ACID; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TREOSULFAN; UNINDEXED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANAPHYLACTIC SHOCK; ASPERGILLOSIS; BACTERIAL INFECTION; BLOOD SMEAR; CONSENSUS; CYTOMEGALOVIRUS INFECTION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ENDOTHELIUM LESION; ENZYME ACTIVITY; ENZYME DEFICIENCY; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INVASIVE CANDIDIASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; LOADING DRUG DOSE; MORTALITY; PATHOPHYSIOLOGY; PLASMAPHERESIS; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANTIBODIES, MONOCLONAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; MICROCIRCULATION; PLASMA EXCHANGE; POLYDEOXYRIBONUCLEOTIDES; PROGNOSIS; RISK FACTORS; SYNDROME; THROMBOSIS;

EID: 60549096492     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969020-00004     Document Type: Review

References (146)

1. National Marrow Donor Program®. Facts and figures [online]. Available from URL: http://www.marrow.org/NEWS/MEDIA/Facts-and-Figures/facts-figures.pdf [Accessed 2008 Nov 13]
2. Burt RK, Loh Y, Pearce W, et al. Clinical applications of blood-derived and marrow-derived stem cells for non-malignant diseases. JAMA 2008; 299: 925-36
3. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Eng J Med 2001; 344: 175-81
4. Batts E, Lazarus HM. Diagnosis and treatment of transplantation- associated thrombotic microangiopathy: real progress or are we still waiting? Bone Marrow Transplant 2007; 40: 709-19
5. George JN, Li X, McMinn JR, et al. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic hematopoietic stem cell transplantation: a diagnostic dilemma. Transfusion 2004; 44: 294-304
6. Worel N, Greinix HT, Leitner G, et al. ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: close association with transplant-associated microangiopathy. Transfus Apher Sci 2007; 36: 297-304
7. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 495-504
8. Zeigler ZR, Shadduck RK, Nemunaitis J, et al. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 1995; 15: 247-53
9. Iacopino P, Pucci G, Arcese W, et al. Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant 1999; 24: 47-51
10. Ruutu T, Hermans J, Niederwieser D, et al. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 1112-9
11. Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001; 113: 58-64
12. Daly AS, Xenocostas A, Lipton JH. Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant 2002; 30: 709-15
13. Ho VT, Cutler C, Carter S, et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571-5
14. Elliott MA, Nichols WL, Plumhoff EA, et al. Post-transplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc 2003; 78: 421-30
15. Sadler JE. Thrombotic thrombocytopenic purpura: a moving target. Hematol Am Soc Hematol Educ Program 2006: 415-20
16. Terrell DR, Williams LA, Vesely SK. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005; 3: 1432-6
17. Huang J, Roth R, Heuser JE, et al. Integrin αvβ3 on human endothelial cells bind von Willebrand factor strings under fluid shear stress. Blood 2009; 113 (7): 1589-97. Epub 2008 Oct 16
18. Rock G, Shumak KH, Sutton DM, et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996; 94: 383-6
19. Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097-103
20. Feyes HB, Liu F, Dong N, et al. ADAMTS-13 plasma level determination uncover antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost 2006; 4: 955-62
21. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-94
22. Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-84
23. Manea M, Kristoffersson AC, Tsai HM, et al. ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr 2007; 166: 249-57
24. Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003; 14: 1072-81
25. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost 2003; 1: 625-31
26. Lammle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005; 3: 1663-75
27. Jimenez JJ, Jy W, Mauro LM, et al. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol 2001; 112: 81-90
28. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-36
29. Mitra D, Jaffe E, Weksler B, et al. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induced apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997; 89: 1224-34
30. Starke R, Machin S, Scully M, et al. The clinical utility of ADAMTS13 activity, antigen, and autoantibody assays in thrombotic thrombocytopenic purpura. Br J Haematol 2007; 136: 649-55
31. Bohm M, Betz C, Miesbach W, et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 2005; 129: 644-52
32. van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999; 93: 3798-802
33. Kentouche K, Zintl F, Angerhaus D, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in the course of stem cell transplantation. Semin Thromb Hemost 2006; 32: 98-104
34. Peyvandi F, Siboni SM, Lambertenghi Deliliers D, et al. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation. Br J Haematol 2006; 134: 187-95
35. Fuge R, Bird I, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001; 113: 58-64
36. Holler E, Kolb HJ, Hiller E, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft versus-host disease after HLA-identical bone marrow transplantation. Blood 1989; 73: 2018-24
37. Chappell ME, Keeling DM, Prentice HG. Haemolytic-uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation? Bone Marrow Transplant 1988; 3: 339-47
38. Dang CT, Magid M, Weksler B, et al. Enhanced endothelial apoptosis in splenic tissue of patients with thrombotic thrombocytopenic purpura. Blood 1999; 93: 1264-70
39. Goon PK, Lip GY, Boos CJ, et al. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006; 8: 79-88
40. Jimenez JJ, Jy W, Mauro LM, et al. Endothelial microparticles released in thrombotic thrombocytopaenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol 2003; 123: 896-902
41. Morel O, Toti F, Hugel B, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscl Thromb Vasc Biol 2006; 26: 2594-604
42. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-3
43. Jy W, Jimenz J, Mauro LM, et al. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation. J Thromb Haemost 2005; 3: 1301-8
44. Pihusch V, Rank A, Steber R, et al. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients. Transplantation 2006; 81: 1405-9
45. Nomura S, Ishii K, Kanazawa S, et al. Significance of elevation in cell-derived microparticles after allogeneic stem cell transplantation: transient elevation of platelet-derived microparticles in TMA/TTP. Bone Marrow Transplant 2005; 36: 921-2
46. Cohen H, Bull HA, Seddon A, et al. Vascular endothelial cell function and ultrastructure in thrombotic microangiopathy following allogeneic bone marrow transplantation. Eur J Hematol 1989; 43: 207-14
47. Takatsuka H, Wakae T, Mori A, et al. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome following allogeneic bone marrow transplantation. Bone Marrow Transplant 2002; 29: 907-11
48. Testa S, Manna A, Porcellini A, et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant 1996; 18: 383-8
49. Salat C, Holler E, Kolb H-J, et al. Endothelial cell markers in bone marrow transplant recipients with and without acute graft versus host disease. Bone Marrow Transplant 1997; 19: 909-14
50. Nurnberger W, Michelmann I, Burdach S, et al. Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998; 76: 61-5
51. Schmaier AH, Srikanth S, Elghetany MT, et al. Hemostatic/fibrinolytic protein changes in C3H/HeN mice infected with Rickettsia conorii: a model for rocky mountain spotted fever. Thromb Haemost 2001; 86: 871-9
52. Qu L, Kiss JE. Thrombotic microangiopathy in transplantation and malignancy. Semin Thromb Hemost 2005; 31: 691-9
53. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-43
54. Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004; 33: 189-95
55. Ruutu T, Giovanni B, Benjamin RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95-100
56. Arai S, Allan C, Streiff M, et al. von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J 2001; 2: 292-9
57. Kersting S, Verdonck LF. Stem cell transplantation nephropathy: a report of six cases. Biol Blood Marrow Transplant 2007; 13: 638-43
58. George JN. Clinical practice: thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-35
59. Studt JD, Hovinga JA, Radonic R, et al. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twins. Blood 2004; 103: 4195-7
60. Chandler WL, Jelacic S, Boster DR, et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346: 23-32
61. Tsai HM, Chandler WL, Sarode R, et al. von Willebrand factor and von Willebrand factor -cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001; 49: 653-9
62. Bennett CL, Kim B, Zakarija A, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol 2007; 50: 1138-43
63. Tsai HM, Rice L, Sarode R, et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000; 132: 794-9
64. Laurence J, Mitra D, Steiner M, et al. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial. Blood 1996; 87: 3245-54
65. Fontana S, Gerritsen HE, Kremer-Hovinga J, et al. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol 2001; 1: 100-2
66. Uderzo C, Bonanomi S, Alessandro B, et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006; 82: 638-44
67. Paquette RL, Tran L, Landaw EM. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis. Bone Marrow Transplant 1998; 22: 351-7
68. Nakamae H, Yamane T, Hasegawa T, et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. Am J Hematol 2006; 81: 525-31
69. Kalhs P, Brugger S, Schwarzinger I, et al. Association with cyclosporine and methylprednisone for graft versus-host disease prophylaxis. Transplantation 1995; 60: 949-57
70. Roy V, Rizvi MA, Vesely SK, et al. Thrombotic thrombocytopenic purpura-like syndromes following bone marrow transplantation: an analysis of associated conditions and clinical outcomes. Bone Marrow Transplant 2001: 27: 641-6
71. Takatsuka H, Nakajima T, Nomura K, et al. Change in clotting factors (7, 9 and 10) and hepatocyte growth factor in patients with thrombotic microangiopathy after bone marrow transplantation. Clin Transplant 2006; 20: 640-3
72. Uderzo C, Fumagalli M, De Lorenzo P, et al. Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1005-9
73. Daly AS, Hasegawa WS, Upton JH, et al. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver. Transfus Apher Sci 2002; 27: 3-12
74. Shulman H, Striker G, Deeg HJ, et al. Nephrotoxicity of cyclosporine A after allogeneic marrow transplantation-glomerular thromboses and tubular injury. N Engl J Med 1981; 305: 1392-5
75. Wolff D, Wilhelm S, Hahn J, et al. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease. Bone Marrow Transplant 2006; 38: 445-51
76. Kersting S, Koomans HA, Hene RJ, et al. Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors, and survival. Bone Marrow Transplant 2007; 39: 359-65
77. Kobashigawa J, David K, Morris AH, et al. Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. Transplant Proc 2005; 37: 1333-9
78. Bombeli T, Muller M, Straub PW, et al. Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood. J Lab Clin Med 1996; 127: 621-34
79. Howard MA, Williams LA, Terrell DR, et al. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2006; 46: 154-6
80. Cutler C, Henry NL, Magee C, et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551-7
81. Couriel DR, Saliba R, Escalon MP, et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005; 130: 409-17
82. Takatsuka H, Wakae T, Mori A, et al. Endothelial damage caused by cytomegalovirus and human herpesvirus-6. Bone Marrow Transplant 2003; 31: 475-9
83. Shimoni A, Yeshurun M, Hardan I, et al. Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: the incidence is not reduced. Biol Blood Marrow Transplant 2004; 19: 484-93
84. Sarkodee-Adoo C, Sotirescu D, Sensenbrenner L, et al. Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. Transfusion 2003; 359: 2078-83
85. Kavanagh D, Goodship TH, Richards A. Atypical haemolytic uraemic syndrome. Br Med Bull 2006; 77-78: 5-22
86. Martinez MT, Bucher CH, Stussi G, et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 2005; 36: 993-1000
87. Kida Y, Ishii T, Ando M, et al. A case report of thrombotic thrombocytopenic purpura and severe acute renal failure post non-myeloablative allogeneic peripheral stem cell transplantation treated with plasma exchange and hemodialysis. Ther Apher Dial 2007; 11: 402-6
88. Llamas P, Romero R, Cabrera R, et al. Management of thrombotic microangiopathy following allogeneic transplantation: what is the role of plasma exchange? Bone Marrow Transplant 1997; 20: 305-6
89. Teruya J, Styler M, Verde S, et al. Questionable efficacy of plasma exchange for thrombotic thrombocytopenic purpura after bone marrow transplantation. J Clin Apher 2001; 16: 169-74
90. Rock G, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 6: 393-7
91. Rock G, Shumak KH, Kelton J, et al. Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Canadian Apheresis Study Group. Transfusion 1992; 32: 710-14
92. Goebel J, Stevens E, Forrest K, et al. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events. Transpl Immunol 2000; 8: 153-9
93. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantion. N Engl J Med 2005; 352: 2705-13
94. Wiseman LR, Faulds D. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs 1999; 58: 1029-42
95. Vincenti F, Nashan B, Light S. Daclizumab: outcome of phase III trials and mechanism of action. Transplant Proc 1998: 30; 2155-8
96. Ekberg H, Backman L, Tufveson G, et al. Daclizumab prevents acute rejection and improve patient survival post transplantation: 1 year pooled analysis. Transpl Int 2000; 13: 151-9
97. Nussenblatt RB, Thompson DJ, Li Z, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003; 21: 283-93
98. Martin R. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis. Neurodegener Dis 2008; 5: 23-6
99. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 2004; 101: 8705-8
100. Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69: 785-9
101. Sloand EM, Scheinberg P, Maciejewski J, et al. Brief communication: successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (Daclizumab). Ann Intern Med 2006; 144: 181-5
102. Maciejewski JP, Sloand EM, Nunez O, et al. Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia. Blood 2003; 102: 3584-6
103. Blaise D, Olive D, Michallet M, et al. Impairment of leukaemia-free survival by addition of interleukin-2receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995; 68: 1144-6
104. Hui CH, Sia H, Mangos H. Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients [letter]. Bone Marrow Transplant 2008; 41: 409-10
105. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161-5
106. Mottershead M, Neuberger J. Daclizumab. Expert Opin Biol Ther 2007; 7: 1583-96
107. Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 2007; 25: 3599-603
108. Willenbacher W, Basara N, Blau I, et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001; 112: 820-3
109. San T, Moini H, Emerk K, et al. Protective effect of defibrotide on perfusion induced endothelial damage. Thromb Res 2000; 99: 335-41
110. Schroder H. Defibrotide protects endothelial cells, but not L929 tumour cells, from tumor necrosis factor-α-mediated cytotoxicity. J Pharm Pharmocol 1995; 47: 250-2
111. Sala M, Leone MP, Lampugnani P, et al. Polydeoxy-ribonucleotide (defibrotide) protects against post-ischemic behavioral, electroencephalographic and neuronal damage in gerbil. Eur J Pharmacol 1997; 328: 143-52
112. Sucak GT, Aki ZS, Yagci M, et al. Treatment of sinusoidal obstruction syndrome with defibrotide: a single-center experience. Transplant Proc 2007; 39: 1558-63
113. Chalandon Y, Roosnek E, Mermillod B, et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 347-54
114. Falanga A, Vignoli A, Marchetti M, et al. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003; 17: 1636-42
115. Pogliani EM, Perseghin P, Parma M, et al. Defibrotide in recurrent thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost 2000; 6: 69-70
116. Rollins BJ. Hepatic veno-occlusive disease. Am J Med 1986; 81: 297-306
117. Bulley SR, Strahm B, Doyle J, et al. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer 2007; 48: 700-4
118. Besisik SK, Ozturk GB, Caliskan Y, et al. Complete resolution of transplantation-associated thrombotic microangiopathy and hepatic veno-occlusive disease by defibrotide and plasma exchange. Turk J Gastroenterol 2005; 16: 34-7
119. Bairey O, Kirgner I, Yakobi M, et al. Clinical severe hepatic venoocclusive disease during induction treatment of acute monoblastic leukemia managed with defibrotide. Am J Hematol 2002; 69: 281-4
120. Ho VT, Linden E, Revta C, et al. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. Semin Thromb Hemost 2007; 33: 373-88
121. Sayer HG, Will U, Schilling K, et al. Hepatic veno-occlusive disease (VOD) with complete occlusion of liver venules after tandem autologous stem cell transplantation: successful treatment with high-dose methylprednisolone and defibrotide. J Can Res Clin Oncol 2002; 128: 148-52
122. Saviola A, Luppi M, Potenza L, et al. Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide. Br J Haematol 2003; 123: 752-3
123. Corbacioglu S, Hönig M, Lahr G, et al. Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant 2006; 38: 547-53
124. Dignan F, Gujral D, Ethell M, et al. Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 2007; 40: 79-82
125. Corti P, Uderzo C, Tagliabue A, et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation [letter]. Bone Marrow Transplant 2002; 29: 542-3
126. Artesani MC. Anaphylactic shock to defibrotide [letter]. Allergy 2006; 61: 1022
127. Reddy PS, Deauna-Limayo D, Cook JD, et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol 2005; 84: 232-5
128. Scully M, Cohel H, Cavenagh J, et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2006; 136: 451-61
129. Ahmad A, Aggarwal A, Sharma D, et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol 2004; 77: 171-6
130. George JN, Woodson RD, Kiss JE, et al. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the transfusion medicine/hemostasis clinical trials network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apheresis 2006; 21: 49-56
131. Fakhouri F, Vernant JP, Veyradier A, et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 2005; 106: 1932-7
132. Au WY, Ma ES, Lee TL, et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol 2007; 137: 475-8
133. Ostronoff M, Ostronoff F, Calixto R, et al. Life-threatening hemolytic-uremic syndrome treated with rituximab in an allogeneic bone marrow transplant recipient [letter]. Bone Marrow Transplant 2007; 39: 649-51
134. Gallerani E, Lerch E, Romagnani E, et al. Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation formultiplemyeloma successfully treated with rituximab. Eur J Haematol 2006; 77: 527-9
135. Au WY, Lie A, Kwong YL. Rituximab in thrombotic microangiopathy: response to Castagna, et al. [letter]. Br J Haematol 2007; 139: 166-67
136. Carson KR, Evens AM, Rosen ST, et al. Progressive multifocal leukoencephalopathy associated with rituximab treatment of B-cell lymphoproliferative disorders: a report of 29 cases from the RADAR Project [abstract no. 370]. Blood 2007; 110 Suppl.: 116a
137. Schleintz N, Ebbo M, Mazodier K, et al. Rituximab as preventative therapy of a clinical relapse in TTP with ADAMTS13 inhibitor. Am J Hematol 2007; 82: 417-8
138. Kebriaei P, Saliba RM, Ma C, et al. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 2006; 38: 203-9
139. Takatsuka H, Takemoto Y, Iwata N, et al. Oral eicosapentaenoic acid for complications of bone marrow transplantation. Bone Marrow Transplant 2001; 28: 769-74
140. Yonezawa Y, Hada T, Uryu K, et al. Inhibitory effect of conjugated eicosapentaenoic acid on mammalian DNA polymerase and topoisomerase activities and human cancer cell proliferation. Biochem Pharmacol 2005; 70: 453-60
141. Chello M, Goffredo C, Patti G, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. Eur J Cardiothorac Surg 2005; 28: 805-10
142. Patti G, Chello M, Pasceri V, et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of Myocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006; 48: 1560-6
143. Boehme MW, Gao IK, Norden C, et al. Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results. Rheumatol Int 2006; 26: 340-7
144. Bohm F, Settergren M, Gonon AT, et al. The endothelin-1 receptor antagonist bosentan protects against ischaemia/reperfusion-induced endothelial dysfunction in humans. Clin Sci (Lond) 2005; 108: 357-63
145. Mori T, Okamoto S, Watanabe R, et al. Successful treatment of bone marrow transplant-associated thrombotic microangiopathy with antithrombin-III. Am J Med 2002; 112: 81-2
146. Hochstetler LA, Flanigan MJ, Lager DJ. Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy. Am J Kidney Dis 1994; 23: 444-50